Supernus Pharmaceuticals (SUPN) Stock Rating Reaffirmed by Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday. They currently have a $56.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 16.55% from the company’s current price. Cantor Fitzgerald also issued estimates for Supernus Pharmaceuticals’ FY2019 earnings at $2.39 EPS.

The analysts wrote, “: We reiterate our Overweight rating and $56 PT for SUPN stock. We believe the next 12-18 months will be an important period as the company’s pipeline development prowess is measured by pivotal data from the SPN-810 and SPN-812 clinical programs. We believe either program embodies commercial potential that could match or exceed combined revenues for Trokendi XR and Oxtellar XR. Consequently, although some investors may probe/clamor for evidence of growth through acquisition, we think successful development of either program will be the most important near-to-intermediate-term drivers of SUPN share value.””

Several other research firms have also weighed in on SUPN. Piper Jaffray Companies set a $47.00 price objective on Supernus Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, July 8th. BidaskClub lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 24th. Zacks Investment Research lowered Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. Stifel Nicolaus upped their price objective on Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Finally, Jefferies Financial Group upped their price objective on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $54.09.

SUPN stock opened at $48.05 on Friday. Supernus Pharmaceuticals has a 1-year low of $33.30 and a 1-year high of $61.25. The company has a market capitalization of $2.57 billion, a PE ratio of 38.13 and a beta of 0.83. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.54 and a current ratio of 2.74.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.14. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The company had revenue of $99.54 million for the quarter, compared to analyst estimates of $101.01 million. analysts forecast that Supernus Pharmaceuticals will post 1.98 earnings per share for the current year.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 7,205 shares of the stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $60.00, for a total value of $432,300.00. Following the transaction, the vice president now directly owns 14,705 shares in the company, valued at approximately $882,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Stefan K.F. Schwabe sold 60,000 shares of the stock in a transaction on Monday, June 18th. The shares were sold at an average price of $54.39, for a total value of $3,263,400.00. Following the completion of the transaction, the vice president now owns 21,967 shares in the company, valued at $1,194,785.13. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,000 shares of company stock worth $6,144,826. 6.20% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. SevenBridge Financial Group LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $113,000. Cubist Systematic Strategies LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $203,000. Everence Capital Management Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $205,000. Cim LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $207,000. Finally, NumerixS Investment Technologies Inc acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $204,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

See Also: Marijuana Stocks Investing Considerations

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply